secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-109744
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone reports Q3 net loss $11.9M; PDUFA target Dec 13 for CARDAMYST in PSVT
-------------------------------------------------------------------------------

- Cash, equivalents and short-term investments $82.6M at Sept 30, up from $69.7M at Dec 31, 2024.
- Net loss Q3 $11.9M vs $9.4M a year ago; no revenue reported in either period.
- Commercial expense surged to $4.6M (Q3) from $1.9M on launch prep for potential FDA approval.
- NDA for CARDAMYST (etripamil) under FDA review; PDUFA action date December 13, 2025.
- Completed $48.7M equity offering and amended Royalty Purchase Agreement securing $75M upon approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925109744/0001104659-25-109744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925109744/tm2530945d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer